VTI Overview

Sales Growth: For the first 31 weeks of the fiscal year, net sales reached $173.26 billion, marking a 9.1% increase from the previous year's $158.87 billion.

March Sales Performance: Comparable sales for the five-week retail March period rose by 9.4%, while the 31-week period saw a 7.2% increase, despite having one fewer shopping day due to the Easter holiday shift.

Wholesale and E-commerce Trends: Costco reported an 11% growth in net sales for March, totaling $28.41 billion, with e-commerce sales increasing by 22.5%, excluding certain factors.

Stock Market Sentiment: Retail sentiment around Costco's stock shifted positively, with 23 out of 37 analysts rating it as a 'Buy' or higher, reflecting a nearly 13% gain over the past 12 months.

Tesla Semi Production Timeline: Tesla's full-size Class 8 electric truck, the Semi, is set to begin volume production in the first half of 2026, with vehicle deliveries expected to start this year, expanding Tesla's offerings for commercial customers.

Pricing and Competition: The 500-mile version of the Tesla Semi is quoted at $290,000, which is higher than the initial announcement but still below the industry average for Class 8 electric trucks, amidst rising competition from startups like Windrose.

Vehicle Variants and Range: The Tesla Semi will be available in two variants: standard range (approximately 325 miles) and long range (about 500 miles), with the dedicated factory in Nevada currently in the tooling phase.

Market Sentiment and Stock Performance: Tesla's stock has remained in a bearish territory recently, despite gaining 54% over the past year, reflecting mixed retail sentiment and ongoing challenges in the electric truck market.

FDA Response: The FDA issued a complete response letter regarding the application for RP1 in combination with Nivolumab for advanced melanoma treatment, indicating it cannot approve the application in its current form due to inadequate clinical trial evidence.

Company's Actions: Following the FDA's feedback, Replimune resubmitted its application in October with additional data and analyses, aiming for a decision by April 10.

Stock Market Reaction: Shares of Replimune Group Inc. fell 15% as the FDA's decision deadline approached, reflecting negative sentiment among retail traders regarding the stock.

Future Outlook: Retail sentiment around REPL stock shifted from bullish to neutral, with concerns that the FDA might require a fresh trial for approval, potentially impacting the stock's value significantly.

Michael Saylor's AI-Generated Video: Michael Saylor shared an AI-generated video on X, showcasing a humorous take on Bitcoin's recent rally, where he depicted himself beating out bears while eating chips labeled 'Bitcoin'.

MSTR Stock Ratings and Price Targets: BTIG reiterated a 'Buy' rating on MSTR stock with a price target of $250, indicating a potential upside of over 100%, while the average price target stands at $374.07, suggesting an even higher upside of over 189%.

Bitcoin's Price Movement: Bitcoin's price rose by 5.2% in the last 24 hours, reaching nearly $72,000, amid a shift in retail sentiment from bearish to bullish, although caution remains prevalent among some investors.

MSTR's Stock Performance: MSTR's stock has fallen over 16% year-to-date and more than 50% in the last 12 months, contrasting with Bitcoin's price, which has only declined 9% in the same timeframe.

Stock Surge: Bullfrog AI Holdings Inc. (BFRG) shares rose over 114% in pre-market trading following the announcement of a deal with a major global pharmaceutical company.

Strategic Agreement: The agreement requires Bullfrog AI to utilize its bfLEAP program to identify and prioritize novel drug targets for major depressive disorder (MDD).

Development Goals: The company aims to accelerate its drug discovery and clinical development programs through this partnership.

Market Sentiment: Retail sentiment around Bullfrog AI is currently described as "extremely bullish," with high message volumes noted at the time of reporting.

Tonix Pharmaceuticals Updates: Tonix is evaluating its Tonmya drug for treating major depressive disorder and acute stress disorder, with plans to initiate a U.S. field study in 2027 for its experimental drug TNX-4800 aimed at seasonal prevention of Lyme disease.

Stock Performance: Shares of Tonix Pharmaceuticals (TNXP) have fallen for four consecutive days, although retail sentiment around the stock has increased by 92% in the past 24 hours, with analysts rating it a 'Buy'.

Drug Approvals and Usage: The U.S. FDA approved Tonix's Tonmya for managing fibromyalgia in adults, and over 2,500 patients have started treatment with it since its launch in November.

Future Pipeline Candidates: Tonix's pipeline includes TNX-2900 for treating Prader-Willi syndrome, TNX-1500 for preventing kidney transplant rejection, and TNX-1900 for treating migraines, with analysts suggesting a potential upside for the stock.